La chaîne d'options affiche les données clés des options sur actions de Cigna Group à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Cigna Group..

Cigna Group (NYSE:CI) Stock, Chaîne d'Options

THE CIGNA GROUP

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.

Cigna

2025&nbsp;OUTLOOK2
The Cigna Group's outlook2 for full year 2025 consolidated adjusted income from operations1,2 is at least $29.60 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2025 dividends.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">(dollars in millions, except where noted and per share amounts)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;2025 Consolidated Metrics</td>
<td colspan="1" rowspan="1">
Projection for Full Year Ending
December 31,&nbsp; 2025
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Income from Operations, per share1,2</td>
<td colspan="1" rowspan="1">at least $29.60</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Evernorth Adjusted Income from Operations, Pre-Tax1,2</td>
<td colspan="1" rowspan="1">at least $7,200</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2</td>
<td colspan="1" rowspan="1">at least $4,125</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Medical Care Ratio2,4</td>
<td colspan="1" rowspan="1">83.2% to 84.2%</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

News

Guidance

Cigna Group Expects FY2025 Adjusted Earnings Of At Least $29.60 vs $29.68 Est

Earnings

Cigna Group Q2 2025 Adj. EPS $7.20 Beats $7.13 Estimate, Sales $67.134B Beat $62.464B Estimate

AAMI

AAPL

ABBV

ACCO

AGCO

AGIO

ALGM

ALNY

AMZN

APLS

APPF

APTV

ARGX

ASUR

ATEC

ATHM

AUPH

AXTI

BBVA

BCPC

BFAM

BIGC

BIIB

BJRI

BLDR

BOOT

BSAC

CABO

CACC

CCCS

CCEC

CDRO

CIGI

CLAR

CMCSA

CMPS

CMRE

COHN

COHU

COIN

COLM

CORT

CRAI

CUBE

CVCO

CWST

DFIN

DINO

DOUG

DSGR

Earnings Scheduled For July 31, 2025

<a href="https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c">https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c</a>

General

CLOV

EHTH

ELEV

GOCO

' Medicare Part D Drug Plan Premiums Set to Rise'- WSJ

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
Wall Street rallied as a wave of new trade deals — including agreements with Japan, Indonesia, and the Philippines — fueled optimism, pushing the S&amp;P 500 and Nasdaq to fresh record highs. President Donald Trump escalated pressure on Federal Reserve Chair Jerome Powell during an in-person visit, demanding lower rates in light of trade easing.
Investor sentiment remained upbeat despite rising political friction. Treasury yields increased modestly on speculation about compromised Fed independence, amid calls from influential voices like Mohamed El‑Erian suggesting Powell resign to preserve central bank autonomy.
Looking ahead, markets are watching progress in U.S.–EU trade negotiations — including a meeting between Trump and Ursula von der Leyen — and upcoming economic data. Investor focus is also on whether pressure on the Fed may influence its rate path or institutional reputation.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46607168/google-stock-roars-as-analysts-race-to-raise-price-targets">"Google stock roars as analysts race to raise price targets"</a>, by Chris Katje, reports that Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) delivered its tenth straight quarter of earnings beats — including $96.43 billion in Q2 revenue and $2.31 EPS — prompting firms to raise their price targets on strength in AI‑driven growth across Cloud, Search, and Ads.
<a href="https://www.benzinga.com/markets/earnings/25/07/46587855/t-mobile-stock-climbs-after-q2-results-crushed-growth-records">"T‑Mobile stock climbs after Q2 results ‘crushed' growth records"</a>, by Erica Kollmann, reports that T‑Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) beat Q2 estimates with $2.84 EPS and $21.13 billion in revenue, added a record 1.7 million postpaid customers — driving upwardly revised FY2025 guidance — and sent shares higher.
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46590824/lendingtree-stock-climbs-as-company-signals-stronger-growth-ahead">"LendingTree stock climbs as company signals stronger growth ahead"</a>, by Akanksha Bakshi, reports that LendingTree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) shares rose after the company highlighted improving lead quality and customer acquisition metrics — citing momentum in core marketplaces and new verticals as drivers of expected stronger growth ahead.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/markets/earnings/25/07/46559708/capital-one-stock-climbs-on-strong-q2-eps-despite-revenue-miss">Capital One Stock Climbs On Strong Q2 EPS, Despite Revenue Miss</a>
<a href="https://www.benzinga.com/markets/earnings/25/07/46618339/coursera-stock-rockets-20-higher-after-q2-earnings-report-heres-why">Coursera Stock Rockets 20% Higher After Q2 Earnings Report: Here's Why</a>
<a href="https://www.benzinga.com/markets/earnings/25/07/46588567/quantumscape-announces-better-than-expected-q2-results-expands-collaboration-with-powerco">QuantumScape Announces Better-Than-Expected Q2 Results, Expands Collaboration With PowerCo</a>

The Bears
<a href="https://www.benzinga.com/markets/earnings/25/07/46612958/molina-healthcare-stumbles-cigna-cvs-humana">"Centene, Cigna, Others Drop As Molina's Results Rattle Sector"</a>, by Vandana Singh, reports that Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) missed Q2 earnings expectations — posting $5.48 EPS vs. $6.21 consensus — even as revenue topped estimates, and slashed its 2025 EPS guidance to just over $19 (from $21.50-$22.50), sending shares of Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and others sharply lower on concerns about medical cost trends and sector-wide risk.
<a href="https://www.benzinga.com/news/fda/25/07/46544331/fda-rejects-replimunes-blood-cancer-drug-stock-sinks">"FDA rejects Replimune's blood cancer drug, stock sinks"</a>, by Erica Kollmann, reports that Replimune Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares plunged after the FDA rejected the company's investigational oncolytic virus therapy for blood cancers, citing deficiencies in clinical data and risk-benefit analysis — prompting investor concern about future development timelines and capital needs.
<a href="https://www.benzinga.com/markets/earnings/25/07/46589727/viking-therapeutics-stock-slides-after-company-misses-q2-earnings-estimates">"Viking Therapeutics stock slides after company misses Q2 earnings estimates"</a>, by Adam Eckert, reports that Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares tumbled after reporting a Q2 loss of $0.58 per share — wider than the expected $0.46 loss — while R&amp;D expenses surged to $60.2 million and the company ended the quarter with $808 million in cash.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46606784/c3-ai-stock-is-tumbling-thursday-whats-going-on">C3 AI Stock Is Tumbling Thursday: What's Going On?</a>
<a href="https://www.benzinga.com/markets/large-cap/25/07/46641084/wall-street-stock-bubble-2025">Is A Stock Market Crash Imminent? Bubble Warnings Grow Louder</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46569958/mara-holdings-stock-is-moving-lower-wednesday-heres-why">MARA Holdings Stock Is Moving Lower Wednesday: Here's Why</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

Markets

COUR

GOOGL

MARA

REPL

TMUS

TREE

VKTX

Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets

Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) missed Wall Street expectations in its second-quarter earnings report Wednesday, triggering a selloff across the <a href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance">healthcare insurance sector</a>. 
Shares of Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Tenet Healthcare Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) all traded lower Thursday as investors reacted to Molina's earnings miss and lowered 2025 guidance, citing rising medical costs and utilization trends.
What Happened: On Wednesday after close, Molina reported second-quarter adjusted earnings of $5.48 per share, missing the consensus of $6.21 and the preliminary expectation of approximately $5.50 per share.
The insurance company reported sales&nbsp;of $11.43 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.93 billion</a>.
Molina&#8217;s second quarter results reflect a &#8220;challenging medical cost trend environment," said Joseph Zubretsky, President and Chief Executive Officer. "The current earnings pressure we are experiencing results from what we believe to be a temporary dislocation between premium rates and medical cost trend which has recently accelerated.&#8221;
Molina is still performing near its long-term target ranges, and the long-term outlook remains the same, he added.
<ul class="wp-block-list">
<li>The consolidated Medical Care Ratio (MCR) for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46586998/molina-healthcare-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">second quarter of 2025 was 90.4%</a>.</li>
<li>The Medicaid MCR was 91.3%. The company experienced medical cost pressure due to continued utilization of behavioral health, pharmacy, and inpatient and outpatient services.</li>
<li>The Medicare MCR was 90.0%, reflecting higher utilization among high-acuity members, particularly for long-term services, supports, and pharmacy.</li>
<li>The Marketplace MCR was 85.4%. Approximately 300 basis points were due to prior-year member reconciliations and a higher "new store" MCR related to the ConnectiCare acquisition.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers" target="_blank" rel="noreferrer noopener">Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?</a>
On Wednesday, Molina further revised its 2025 earnings guidance from $21.50-$22.50 to over $19 per share.
Notably, Centene withdrew its 2025 GAAP and adjusted diluted EPS guidance. This stems from its initial review of 2025 industry data from Wakely, an <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" target="_blank" rel="noreferrer noopener">independent actuarial firm</a>.
Molina Healthcare forecasts fiscal 2025 sales&nbsp;of $44 billion compared to the consensus of $44.19 billion.
It forecasts a 2025 consolidated MCR of 90.2%, with Medicaid MCR of 90.9%, Medicare MCR of 90% and Marketplace MCR of 85.1%.
Readers should also note that the largest insurance company, UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), is also trading lower on Thursday. In an SEC filing on Thursday, the company said it has now begun complying with the Department's formal criminal and civil requests. UnitedHealth says it has full confidence in its practices and is committed to working cooperatively with the <a target="_blank" href="https://www.benzinga.com/news/legal/25/07/46605691/unitedhealth-under-federal-scrutiny-reaffirms-integrity-of-its-medicare-operations" rel="noreferrer noopener">Department throughout this process</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/restaurants/25/07/46606785/chipotle-mexican-grill-q2-sales-decline-june-july-boost-keeps-analysts-bullish" target="_blank" rel="noreferrer noopener">Chipotle Mexican Grill Q2 Sales Decline, June-July Boost Keeps Analysts Bullish</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Movers

Trading Ideas

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Centene, Cigna, Others Drop As Molina's Results Rattle Sector

WIIM

Shares of health insurers are trading lower in sympathy with Molina Healthcare, which issued soft guidance. The sector may also be under pressure after UnitedHealth said  it has now begun complying with the DOJ's formal criminal and civil requests.

Shares of health insurers are trading lower amid a selloff in the sector following Elevance's recent soft guidance and broader concerns over rising medical costs.

<a href="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c" title="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c">https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c</a>

Biotech

Reported Earlier: 'Obamacare Insurers Seek Double-Digit Premium Hikes Next Year; Some Enrollees Could Be Hit With Increases Of More Than 20% Because Of Federal Changes And Higher Health Expenses' - WSJ Exclusive

https://www.nytimes.com/2025/07/18/health/health-insurance-prescription-claim-denials.html#:~:text=Prescription%20drug%20denials%20by%20private,nation's%20private%20health%20insurance%20system.

Reported Earlier: 'Health Insurers Are Denying More Drug Claims, Data Shows' - NY Times

Shares of health insurance stocks are trading lower in sympathy with Elevance Health after the company reported mixed Q2 financial results and cut its FY25 adjusted EPS guidance.

Financial giants have made a conspicuous bearish move on Cigna Group. Our analysis of options history for Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) revealed 17 unusual trades.
Delving into the details, we found 23% of traders were bullish, while 64% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $765,142, and 4 were calls, valued at $432,675.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $300.0 and $340.0 for Cigna Group, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cigna Group's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cigna Group's substantial trades, within a strike price spectrum from $300.0 to $340.0 over the preceding 30 days.
<h3>Cigna Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752696057_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$51.8</td>
<td>$50.2</td>
<td>$50.2</td>
<td>$300.00</td>
<td>$336.3K</td>
<td>309</td>
<td align="right">70</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$13.9</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$315.00</td>
<td>$108.7K</td>
<td>1.2K</td>
<td align="right">500</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$14.0</td>
<td>$12.9</td>
<td>$12.9</td>
<td>$315.00</td>
<td>$96.7K</td>
<td>1.2K</td>
<td align="right">581</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$12.8</td>
<td>$12.4</td>
<td>$12.8</td>
<td>$315.00</td>
<td>$64.4K</td>
<td>1.2K</td>
<td align="right">631</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$12.7</td>
<td>$12.3</td>
<td>$12.7</td>
<td>$315.00</td>
<td>$54.6K</td>
<td>1.2K</td>
<td align="right">337</td>
</tr>
</tbody>
</table>

<h3>About Cigna Group</h3>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense (current contract through 2029), and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of December 2024.
After a thorough review of the options trading surrounding Cigna Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Cigna Group's Current Market Status</h3>
<ul>
<li>With a trading volume of 894,988, the price of CI is up by 1.04%, reaching $305.6.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 15 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cigna Group</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $371.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $371.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cigna Group options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Cigna Group Options Trading: A Deep Dive into Market Sentiment

Managed care insurers have faced a turbulent few months, with several major players experiencing steep market capitalization losses amid earnings uncertainty and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">looming policy shifts</a>.
<h2 class="wp-block-heading">UnitedHealth Leads The Downturn Amidst Guidance Withdrawal And CEO Resignation</h2>
UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) led the downturn with a staggering 40.9% drop in market cap in the second quarter and a 39.6% decline year over year, triggered largely by its decision to withdraw 2025 earnings guidance.
UnitedHealth&#8217;s CEO, Andrew Witty, resigned for personal reasons, and the previous CEO, Stephen Hemsley, succeeded him. The company also <a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">withdrew 2025 guidance</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices" rel="noreferrer noopener">UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices</a>
Despite the significant drop, UnitedHealth retained its top spot as the largest U.S. insurer, with a market cap of $283 billion, well ahead of second-ranked The Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), which stood at $156.44 billion.
<h2 class="wp-block-heading">Managed Care Suffers While Property And Casualty Gains</h2>
An analysis by S&amp;P Global of the 20 largest U.S. insurers by market capitalization highlighted a sharp divide between segments.
Among the eight companies that saw market cap declines of more than 5%, half were managed care firms. In contrast, five of the six insurers with gains were property and casualty providers, reflecting stronger investor confidence in that sector.
<h2 class="wp-block-heading">Ripple Effect: Other Health Insurers Follow Suit</h2>
Other health insurers followed UnitedHealth&#8217;s downward trajectory. Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) saw its market cap drop 10.3% in the second quarter, while Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) declined 10.8%. Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) posted more modest losses of 7.6% and 1%, respectively.
<h2 class="wp-block-heading">Third-Quarter Woes Intensify With Policy Uncertainty</h2>
The pressure has extended into the third quarter. Last week, Centene also <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" rel="noreferrer noopener">withdrew its 2025 guidance</a>, sending the market into shock. The result was a 40.37% stock plunge in a single day. The fallout also affected peers, with UnitedHealth and Elevance falling 5.7% and 11.5%, respectively.
Investor sentiment was further rattled by President Donald Trump&#8217;s proposed One Big Beautiful Bill Act, which appears close to congressional approval.
The S&amp;P <a target="_blank" href="https://www.spglobal.com/market-intelligence/en/news-insights/articles/2025/7/unitedhealth-remains-largest-us-insurer-by-market-cap-after-40-hit-in-q2-2025-91405077" rel="noreferrer noopener">report</a> added that the legislation could significantly impact Medicaid access, a key business area for managed care insurers like UnitedHealth and Centene that administer the program through government funding. The policy risk triggered another selloff in the first week of the third quarter.
<h2 class="wp-block-heading">Broader Insurance Industry Shows Resilience</h2>
Still, the broader insurance industry has shown resilience. At the end of the second quarter, the S&amp;P 500 insurance index climbed 19.55% year over year, surpassing the S&amp;P 500&#8217;s 15.16% gain during the same period.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46192421/home-health-braces-for-potential-1-billion-cut-in-medicare-payments" target="_blank" rel="noreferrer noopener">Home Health Braces For Potential $1 Billion Cut In Medicare Payments</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

UnitedHealth, Centene Hit Hard By Guidance Shock, Trump's Medicaid Push

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 4.38% on an annualized basis producing an average annual return of 16.8%. Currently, Cigna Group has a market capitalization of $87.03 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 15 years ago, it would be worth $10,218.92 today based on a price of $321.00 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751645713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Cigna Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has risen 8.27% since its last report. The company recently reported that it has 2.95 million shares sold short, which is 1.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.64 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cigna Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751562051_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cigna Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cigna Group's peer group average for short interest as a percentage of float is 10.36%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Cigna Group?

Shares of managed care provider Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) dropped over 40% on Wednesday, marking the worst single-day performance in the company's history.
Check out the current price of&nbsp;<a href="https://www.benzinga.com/quote/CNC" target="_blank" rel="noreferrer noopener">CNC stock here.</a>
What Happened: On CNBC&#8217;s Mad Money, Jim Cramer referred to the collapse as &#8220;a huge hit,&#8221; resulting from a combination of factors such as weak Affordable Care Act enrollments, an actuarial report pointing to sicker patients, and the company&#8217;s decision to <a href="https://www.benzinga.com/markets/guidance/25/07/46209736/centene-withdraws-2025-guidance-shares-dive">pull its 2025 outlook</a>.
&#8220;Companies make forecasts, they&#8217;re supposed to try and beat them,&#8221; Cramer says, however, &#8220;they rarely pull them.&#8221;
According to Cramer, Centene disclosed data from an independent actuarial firm covering 22 of the 29 states where it operates ACA exchange plans.
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46195080/doj-dismantles-14-billion-healthcare-fraud-scheme-in-largest-ever-crackdown-impacting-over-1-million-americans">DOJ Dismantles $14 Billion Healthcare Fraud Scheme In Largest-Ever Crackdown, Impacting Over 1 Million Americans</a>
The findings showed that overall marketplace enrollment growth was lower than expected and that those who did enroll were in poorer health than projected, a combination that significantly affects the company's bottom line, thus prompting the company to pull its guidance.
As a result, the company now expects a $1.8 billion reduction in its projected risk adjustment revenue from the federal government. This drop is expected to slash its 2025 earnings by $2.75 per share.
&#8220;This is horrifying,&#8221; Cramer said, referring to the sharp revision in Centene&#8217;s EPS, from $7.25 per share projected earlier. &#8220;We&#8217;re talking about a 35% to 40% hit to their numbers,&#8221; Cramer says, &#8220;no wonder the stock was eviscerated.&#8221;
Why It Matters: Centene&#8217;s decision to withdraw its guidance, citing the independent actuarial report, led to a sector-wide selloff on Wednesday. 
All of Centene&#8217;s peers and competitors in the managed care business, such as Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), among others, all falling in tandem during the day. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stocks / ETFs</td>
<td class="has-text-align-center" data-align="center">1 Day</td>
<td class="has-text-align-center" data-align="center">Year-To-Date</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>)</td>
<td class="has-text-align-center" data-align="center">-40.37%</td>
<td class="has-text-align-center" data-align="center">-44.17%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)</td>
<td class="has-text-align-center" data-align="center">-21.97%</td>
<td class="has-text-align-center" data-align="center">-16.79%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)</td>
<td class="has-text-align-center" data-align="center">-11.50%</td>
<td class="has-text-align-center" data-align="center">-4.26%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td class="has-text-align-center" data-align="center">-5.70%</td>
<td class="has-text-align-center" data-align="center">-39.04%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td class="has-text-align-center" data-align="center">-4.19%</td>
<td class="has-text-align-center" data-align="center">+16.72%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">iShares US Healthcare Providers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHF#NYSE">IHF</a>)</td>
<td class="has-text-align-center" data-align="center">-6.27%</td>
<td class="has-text-align-center" data-align="center">-3.16%</td>
</tr>
</tbody>
</table>
</figure>
This comes amid a potential amendment in the Affordable Care Act, which could lead to an additional $313 billion in <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46163659/senate-republicans-propose-313-billion-cut-in-medicaid-spending-in-trumps-big-beautiful-bill">spending cuts</a> by blocking able-bodied adults without dependent children in Medicaid expansion states from receiving the enhanced 9-to-1 Federal Medical Assistance Percentage (FMAP).
Insurers have also <a href="https://www.benzinga.com/personal-finance/tax/25/06/46012776/brace-for-higher-healthcare-premiums-in-2026-as-insurers-blame-trumps-tariffs-in-filings-to-regulators-report">warned of higher premiums</a> in 2026, placing the blame on President Donald Trump&#8217;s tariffs, which are expected to increase the cost&nbsp;of prescription drugs, medical devices,&nbsp;and other medical products and&nbsp;services.
Price Action: Shares of Centene dropped 40.37% on Wednesday, closing at $33.78, but are up 1.10% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="143" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-1024x143.png" alt="" class="wp-image-971299" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-1024x143.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-300x42.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-768x107.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM.png 1532w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Centene scores well on Value and Growth, but has an unfavorable price trend in the short, medium and long term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights on the stock, as well as its peers and competitors in the managed care space.
Photo courtesy: katz / Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/06/46166087/mark-cuban-slams-insurers-over-high-deductibles-urges-josh-hawley-to-change-the-game-with-two-part-plan">Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To &#8216;Change The Game&#8217; With Two-Part Plan</a></li>
</ul>

iShares Dow Jones US Health Care Provides Index Fund

Jim Cramer On Centene's 40% Crash: Fewer ACA Signups, Sicker Patients, Pulled Guidance And Major Earnings Hit Trigger Selloff: 'This Is Horrifying'

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/" title="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>
&nbsp;

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

Shares of health insurers are trading higher as a Republican legislative package targeting tax and healthcare changes faces obstacles in the US Senate.

RBC Capital analyst Ben Hendrix reiterates Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and maintains $371 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on Cigna Group, Maintains $371 Price Target

Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and its subsidiary Celgene Inc. face antitrust <a href="https://www.benzinga.com/topic/legal">allegations in a civil lawsuit</a>.
Cigna Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) accuses both companies of unlawfully extending their monopoly on the multiple myeloma drug pomalidomide, marketed as Pomalyst.
The complaint argues that the pharmaceutical giants engaged in fraudulent patent practices, abuse of the court system, and anticompetitive deals to delay generic competition, resulting in billions of dollars in overcharges to drug purchasers.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug" rel="noreferrer noopener">Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug</a>
Purchasers of this $2.25 billion a year drug—like Cigna—have overpaid for pomalidomide by many hundreds of millions, &#8220;if not billions, of dollars,&#8221; the lawsuit alleged.
Bloomberg Law published a copy of the lawsuit online Tuesday.
According to the lawsuit, Celgene secured method-of-use and formulation patents for pomalidomide by intentionally misleading the U.S. Patent and Trademark Office.
The company allegedly withheld information about earlier patents from a Boston Children's Hospital doctor and submitted false expert declarations claiming they overcame "unexpected" drug stability issues.
The suit claims those statements were knowingly false, as scientists had long addressed such challenges with thalidomide analogs through standard techniques. Without this fraudulent conduct, the patents would not have been granted, and generics could have entered the market earlier.
Celgene also allegedly filed a series of sham lawsuits to block potential competitors, fully aware that the patents in question were either invalid or easily circumvented.
These lawsuits were based on patents obtained through fraud or were so weak that no reasonable company could expect to win. Despite this, Celgene pursued litigation to delay generic entry and protect inflated drug prices.
&#8220;The lawsuits were a sham because no reasonable litigant in Celgene's position would have expected to prevail in showing that the patents at issue (method of treatment, formulation, and crystal form) were both valid and infringed,&#8221; Cigna <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/vCelgeneCorporationetalDocketNo125cv05237SDNYJun242025CourtDocket?doc_id=X23NN7JB1SC8AMBB0IK58OQETGN" rel="noreferrer noopener">said</a> in the complaint.
The complaint further alleges that Celgene and Bristol Myers made reverse payments to generic manufacturers to delay market entry.
These settlements, including those tied to another Celgene drug, Revlimid, created coordinated output restrictions and delivered hundreds of millions in excess profits to generic competitors.
The arrangement maintained artificially high prices for Revlimid and Pomalyst. The generic launch for Pomalyst—set for the first quarter of 2026—coincides with the end of the Revlimid restriction. 
The lawsuit claims that Celgene paid generic drugmakers—Aurobindo, Eugia, Breckenridge, Natco, and Teva—to drop their efforts to challenge patents for the drug pomalidomide and delay launching cheaper versions in the U.S. market.
It also alleges that Celgene and Bristol Myers delayed generic versions of Pomalyst by offering large payments for related settlements over another drug, Revlimid.
Pomalyst and Revlimid are prescription medicines used to treat adults with multiple myeloma.
During the first quarter of 2025, Revlimid sales reached $936 million, down 44% year over year. Pomalyst/Imnovid sales fell <a href="https://www.benzinga.com/general/biotech/25/04/44986472/bristol-myers-delivers-upbeat-2025-forecast-after-beating-q1-wall-street-expectations-says-guidance-includes-china-tariffs-impact" target="_blank" rel="noreferrer noopener">24% to $658 million</a>.
Benzinga reached out to Bristol Myers for commentary but have not heard back. 
Price Action: BMY stock is down 0.59% at $46.75 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46095115/from-nyse-to-hong-kong-over-80-chinese-firms-pull-plug-on-us-listings-amid-growing-tensions" target="_blank" rel="noreferrer noopener">From NYSE To Hong Kong: Over 80 Chinese Firms Pull Plug On US Listings Amid Growing Tensions</a></li>
</ul>
Image: Shutterstock

Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2 Billion Cancer Drug

Press Releases

The Cigna Group Health Equity Impact Fund Opens 2025 Grants

New PPO Dental Plans More Competitive Against HMOs

Cigna Healthcare Unveils Industry-Leading AI-Powered Digital Tools for a Simple and Reliable Customer Experience

Small Cap

AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers

The Cigna Group's Second Quarter 2025 Earnings Release Details

The Cigna Group Foundation Announces Grants to 24 Nonprofits, Builds on Momentum to Help Address Youth Mental Health Crisis

The Cigna Group Foundation Addresses Mental Health and Housing Stability for Veterans with $3 Million in Grants

Opinion

Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning

Dividends

The Cigna Group Declares Quarterly Dividend

The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

AVAI

GEHC

RDNT

SOUN

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Cigna Group

Cigna Group (CI) Options

Loading...

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL